Plasma Homocysteine and Insulin in Diabetic Nephropathy: Relationship to Body Mass Index

Figures & data

Figure 1.

Table 1. Homocysteine, Insulin, and BMI in Various Groups

Group	Homocysteine (µmol/L)	Insulin (U/L)	BMI
A (diabetic nephropathy), n = 50	21.3 ± 7.2	18.6 ± 7.7,	24.3 ± 4.0,
B (diabetics without nephropathy), n = 25	19.4 ± 7.1	25.0 ± 13.7	26.2 ± 3.8
C (healthy controls), n = 25	11.5 ± 2.3	13.6 ± 3.3	21.5 ± 4.2

Mean ± S.D.

^*P < 0.01 compared to C.

^†P < 0.01 compared to B.

Table 2. Relationship of Homocysteine with Insulin

Group	Homocysteine (µmol/L)	Insulin (U/L)	r‐Value	p‐Value
A	21.3 ± 7.2	18.6 ± 7.7	0.196	> 0.10
B	19.4 ± 7.1	25.0 ± 13.2	− 0.131	> 0.10
C	11.5 ± 2.3	13.6 ± 3.3	− 0.089	> 0.10

Table 3. Association with Body Mass Index

BMI	Cases	Homocysteine	Insulin
Group A (diabetic nephropathy)
19–25	32	20.7 ± 7.2	18.0 ± 7.5
25–30	14	23.0 ± 7.5	20.2 ± 8.0
> 30	04	20.3 ± 6.0	20.3 ± 5.2
r‐value		0.124	0.251
p‐value		> 0.10	< 0.10
Group B (diabetics without nephropathy)
19–25	13	19.6 ± 8.2	29.2 ± 12.3
25–30	10	19.6 ± 6.0	22.4 ± 11.9
> 30	02	20.3 ± 6.0	25.9 ± 10.1
r‐value		− 0.036	− 0.342
p‐value		> 0.10	< 0.10

Table 4. Homocysteine, Insulin, and BMI and the Severity of Diabetic Nephropathy

Group	GFR (ml/min)	Homocysteine (µmol/L)	Insulin (U/L)	BMI
Mild (n = 20)	30–50	20.3 ± 7.0	19.0 ± 7.3	24.7 ± 3.9
Moderate (n = 17)	10–29	23.7 ± 9.6	15.8 ± 7.3	22.2 ± 3.1
Severe (n = 13)	< 10	19.2 ± 4.6	18.7 ± 8.3	23.9 ± 3.52

p > 0.10.